iSpecimen Inc. Announces Pricing of Approximately $2.5 Million Private Placement
Rhea-AI Summary
iSpecimen (Nasdaq: ISPC) priced a private placement for aggregate gross proceeds of approximately $2.5 million, issuing 488,281 common shares at $5.12 per share and offering pre-funded warrants at $5.1199 where exercisable for one share at $0.0001 per share.
The company intends to use net proceeds for working capital, including up to $900,000 for marketing. The offering is expected to close on or about May 11, 2026, is capped at 19.99% of outstanding shares pending stockholder approval, and E.F. Hutton serves as placement agent.
AI-generated analysis. Not financial advice.
Positive
- Approximately $2.5 million of gross proceeds priced in the offering
- Up to $900,000 of proceeds allocated specifically for marketing
Negative
- Aggregate issuable shares are capped at 19.99% until stockholder approval, implying near-term dilution constraints
- Securities were sold only to accredited investors and are unregistered, limiting liquidity until registration
News Market Reaction – ISPC
On the day this news was published, ISPC declined 1.37%, reflecting a mild negative market reaction. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $90K from the company's valuation, bringing the market cap to $6.51M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Among close peers, ADVB (-14.15%) and BIAF (-4.25%) are down, while MYNZ (+5.07%), XWEL (+3.52%) and PRPH (-5.86%) show mixed moves. Momentum data flags BIAF and ADVB both moving down, indicating some broader sector pressure alongside ISPC’s financing news.
Previous Private placement Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 30 | Private placement pricing | Negative | -13.2% | Announced ~$5.5M Series C preferred private placement for working capital. |
| Aug 04 | Private placement closing | Negative | -4.0% | Closed ~$1.75M common stock and pre-funded warrant private placement. |
| Jul 31 | Private placement pricing | Negative | +18.6% | Priced ~$1.75M private placement at-the-market to accredited investors. |
Past private placements often coincided with share price weakness, though one event saw a sharp upside reaction.
Recent history for iSpecimen around capital raises shows repeated use of private placements. A $5.5 million preferred-stock financing on Dec 30, 2025 was followed by a -13.15% move. In late July and early August 2025, a $1.75 million at-the-market private placement first on pricing news and then on closing produced mixed reactions of +18.55% and -3.97%. Today’s private placement continues this pattern of financing tied to working capital and marketing needs.
Historical Comparison
In the past year, ISPC disclosed 3 private placement financings with an average 24h move of 0.48%, showing mixed but often pressured trading around capital raises.
The company has repeatedly raised capital via private placements, from ~$1.75M in mid-2025 to ~$5.5M in Dec 2025, and now announces another financing focused on working capital and marketing.
Regulatory & Risk Context
An effective S-3 registration allows resale of 101,000,000 conversion shares from the December 2025 financing. The company notes it will not receive proceeds from those resales and that large secondary sales could exert downward pressure on the share price. iSpecimen also disclosed that it remains out of compliance with Nasdaq’s $1.00 minimum bid requirement, with a cure deadline of May 18, 2026.
Market Pulse Summary
This announcement details a new private placement expected to raise approximately $2.5 million, issuing 488,281 shares at $5.12 plus pre-funded warrants with a $0.0001 exercise price. Net proceeds are earmarked for working capital, including up to $900,000 for marketing, while total issuable shares are capped at 19.99% of current outstanding pending shareholder approval. In context of prior private placements and an effective registration covering 101,000,000 resale shares, investors may focus on dilution, overhang, and Nasdaq listing compliance metrics.
Key Terms
private placement financial
pre-funded warrants financial
accredited investors financial
Section 4(a)(2) regulatory
Regulation D regulatory
registration statement regulatory
Nasdaq Listing Rules regulatory
registration rights agreement regulatory
AI-generated analysis. Not financial advice.
May 8, 2026
WOBURN, Mass., May 08, 2026 (GLOBE NEWSWIRE) -- iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, today announced that it has priced a private placement with accredited investors for aggregate gross proceeds of approximately
In connection with the offering, the Company will issue 488,281 shares of common stock (the “Shares”) at a purchase price of
The Company intends to use the net proceeds from the offering for working capital purposes, including up to
The offering is expected to close on or about May 11, 2026, subject to the satisfaction of customary closing conditions. Pursuant to the terms of the transaction documents, the aggregate number of shares of common stock issuable to the purchasers in the offering (including upon exercise of the Pre-Funded Warrants and giving effect to any anti-dilution and price adjustment provisions thereunder) is subject to a cap of
E.F. Hutton & Co. is acting as the exclusive placement agent in connection with the offering.
Sichenzia Ross Ference Carmel LLP is serving as counsel to the Company. Zarif Law Group P.C. is serving as counsel to E.F. Hutton & Co. in connection with the offering.
Additional details regarding the offering will be available in a Form 8-K to be filed by the Company with the Securities and Exchange Commission (the “SEC”).
The securities to be issued in connection with the offering described above are being offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the “1933 Act”), and Regulation D promulgated thereunder and have not been registered under the 1933 Act or applicable state securities laws. Accordingly, such securities may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the 1933 Act and such applicable state securities laws. The securities were offered only to accredited investors. Pursuant to a registration rights agreement with the investors, the Company has agreed to file one or more registration statements with the SEC covering the resale of the Shares and the shares of common stock issuable upon exercise of the Pre-Funded Warrants issued in the offering.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About iSpecimen
iSpecimen (Nasdaq: ISPC) offers an online marketplace for human biospecimens, connecting scientists in commercial and non-profit organizations with healthcare providers that have access to patients and specimens needed for medical discovery. Proprietary, cloud-based technology enables scientists to intuitively search for specimens and patients across a federated partner network of hospitals, labs, biobanks, blood centers and other healthcare organizations. For more information, please visit www.ispecimen.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are statements other than statements of historical fact and may be identified by the use of words or expressions such as “may,” “should,” “could,” “would,” “will,” “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “continue,” “seek,” “potential,” “target,” “project,” “forecast,” “outlook,” or similar expressions, or by discussions of strategy, plans, or intentions.
Forward-looking statements in this press release include, without limitation, statements regarding: the expected closing of the offering and the satisfaction of the conditions thereto; the anticipated gross and net proceeds from the offering; the Company’s intended use of proceeds, including for working capital and marketing expenses; the Company’s ability to obtain the approval of its stockholders required under applicable Nasdaq Listing Rules in connection with the offering and the related transaction documents, and the timing thereof; the Company’s ability to timely file and have declared effective a registration statement covering the resale of the shares of common stock issued in the offering and the shares of common stock issuable upon exercise of the Pre-Funded Warrants; the implementation of any anti-dilution, most-favored-nation, or price adjustment provisions contained in the transaction documents; the Company’s ability to maintain compliance with the continued listing standards of The Nasdaq Capital Market; the Company’s ability to continue as a going concern and to access additional capital on acceptable terms, or at all; the Company’s commercial strategy and operations, including the iSpecimen Marketplace and the Company’s relationships with healthcare specimen providers and research customers; and any other statements regarding future events, plans, or expectations.
These forward-looking statements are based on management’s current expectations and assumptions and are subject to risks, uncertainties, and other factors, many of which are beyond the Company’s control, that could cause actual results to differ materially from those expressed or implied. Such risks and uncertainties include, without limitation: the risk that the conditions to closing the offering may not be satisfied on the anticipated timeline or at all; the risk that the Company may fail to obtain the required stockholder approval under applicable Nasdaq Listing Rules within the timeframes contemplated by the transaction documents, or at all, which would limit the Company’s ability to issue additional shares to investors and could trigger the termination of certain price-protection and most-favored-nation provisions; the substantial dilution to the Company’s existing stockholders that may result from the issuance of shares in the offering, the exercise of the Pre-Funded Warrants, and any anti-dilution, most-favored-nation, or price adjustments under the transaction documents; the Company’s ability to maintain compliance with the continued listing standards of The Nasdaq Capital Market and the consequences of any failure to do so on the Company’s ability to raise capital; the substantial doubt regarding the Company’s ability to continue as a going concern and the Company’s need for additional financing to fund its operations; and the other risks and uncertainties described under the heading “Risk Factors” in the Company’s filings with the Securities and Exchange Commission, as well as general business, economic, market, and geopolitical conditions.
Actual results may differ materially from those expressed or implied by these forward-looking statements. Additional information regarding factors that may cause actual results to differ materially is included under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission on April 1, 2026, and in the Company’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission, copies of which are available free of charge through the Securities and Exchange Commission’s website at www.sec.gov. The forward-looking statements in this press release speak only as of the date of this press release. Except as required by applicable law, the Company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances, or otherwise.
